Top

Published in:

01-06-2016 | Review Article

Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma

Authors: L. G. Estévez, E. García, M. Hidalgo

Published in: Clinical and Translational Oncology | Issue 6/2016

Abstract

Aberrations in the PI3K signaling pathway are frequently observed in patients with breast cancer. Because of that, PI3K inhibitors are attractive options for the treatment of breast cancer because PI3K is the most proximal component of the pathway other than receptor tyrosine kinases. Buparlisib is a potent and highly specific oral pan-class I PI3K inhibitor, which is currently under investigation in patients with breast cancer. In this article, we describe the PI3K signaling pathway, the prognostic value of PI3K pathway mutations, as well as the mechanism of action of buparlisib. Lastly, we discuss preliminary results of preclinical and clinical studies showing the efficacy and safety profile of this agent in breast cancer patients.

Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550–62. doi:10.1038/nrc2664.CrossRefPubMed

Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia. 2012;17(3–4):205–16. doi:10.1007/s10911-012-9264-2.CrossRefPubMedPubMedCentral

Escobedo JA, Navankasattusas S, Kavanaugh WM, Milfay D, Fried VA, Williams LT. cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding of PI3-kinase to the PDGF beta-receptor. Cell. 1991;65(1):75–82. doi:10.1016/0092-8674(91)90409-R.CrossRefPubMed

Otsu M, Hiles I, Gout I, Fry MJ, Ruiz-Larrea F, Panayotou G, et al. Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell. 1991;65(1):91–104. doi:10.1016/0092-8674(91)90411-Q.CrossRefPubMed

Skolnik EY, Margolis B, Mohammadi M, Lowenstein E, Fischer R, Drepps A, et al. Cloning of PI3Kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell. 1991;65(1):83–90. doi:10.1016/0092-8674(91)90410-Z.CrossRefPubMed

Myers MG Jr, Backer JM, Sun XJ, Shoelson S, Hu P, Schlessinger J, et al. IRS-1 activates phosphatidylinositol 3′-kinase by associating with src homology 2 domains of p85. Proc Natl Acad Sci USA. 1992;89(21):10350–4.CrossRefPubMedPubMedCentral

Guillermet-Guibert J, Bjorklof K, Salpekar A, Gonella C, Ramadani F, Bilancio A, et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA. 2008;105(24):8292–7. doi:10.1073/pnas.0707761105.CrossRefPubMedPubMedCentral

Stoyanov B, Volinia S, Hanck T, Rubio I, Loubtchenkov M, Malek D, et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science. 1995;269(5224):690–3.CrossRefPubMed

Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273(22):13375–8.CrossRefPubMed

10.

Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995;376(6541):599–602. doi:10.1038/376599a0.CrossRefPubMed

11.

Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 1996;15(23):6541–51.PubMedPubMedCentral

12.

Balendran A, Casamayor A, Deak M, Paterson A, Gaffney P, Currie R, et al. PDK1 acquires PDK2 activity in the presence of a synthetic peptide derived from the carboxyl terminus of PRK2. Curr Biol. 1999;9(8):393–404. doi:10.1016/S0960-9822(99)80186-9.CrossRefPubMed

13.

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307(5712):1098–101. doi:10.1126/science.1106148.CrossRefPubMed

14.

Toker A, Newton AC. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. J Biol Chem. 2000;275(12):8271–4.CrossRefPubMed

15.

Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011;10(11):868–80. doi:10.1038/nrd3531.CrossRefPubMed

16.

Castro AF, Rebhun JF, Clark GJ, Quilliam LA. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem. 2003;278(35):32493–6. doi:10.1074/jbc.C300226200C300226200.CrossRefPubMed

17.

Inoki K, Li Y, Zhu T, Wu J, Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4(9):648–57. doi:10.1038/ncb839ncb839.CrossRefPubMed

18.

Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J. 1996;15(3):658–64.PubMedPubMedCentral

19.

Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 1992;69(7):1227–36. doi:10.1016/0092-8674(92)90643-Q.CrossRefPubMed

20.

Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004;166(2):213–23. doi:10.1083/jcb.200403069jcb.200403069.CrossRefPubMedPubMedCentral

21.

Saura C, Bendell J, Jerusalem G, Grana-Suarez B, Su S, Ru Q et al. PD09-03: Phase I/II Study of BKM120 in Combination with Trastuzumab in Patients with HER2 Overexpressing Metastatic Breast Cancer Resistant to Trastuzumab-Containing Therapy. Cancer Res. 2011;71(suppl 24):Abstract PD09-03. doi:10.1158/0008-5472.sabcs11-pd09-03.

22.

Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008;27(41):5497–510. doi:10.1038/onc.2008.245.CrossRefPubMedPubMedCentral

23.

Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554. doi:10.1126/science.10965021096502.CrossRefPubMed

24.

Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature12113.CrossRefPubMed

25.

Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004;3(8):772–5.CrossRefPubMed

26.

Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, et al. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 2005;65(23):10992–1000. doi:10.1158/0008-5472.CAN-05-2612.CrossRefPubMed

27.

Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009;15(16):5049–59. doi:10.1158/1078-0432.CCR-09-0632.CrossRefPubMed

28.

Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011;10(6):1093–101. doi:10.1158/1535-7163.MCT-10-1089.CrossRefPubMedPubMedCentral

29.

Dupont Jensen J, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res. 2011;17(4):667–77. doi:10.1158/1078-0432.CCR-10-1133.CrossRefPubMed

30.

Boyault S, Drouet Y, Navarro C, Bachelot T, Lasset C, Treilleux I, et al. Mutational characterization of individual breast tumors: tP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast Cancer Res Treat. 2012;132(1):29–39. doi:10.1007/s10549-011-1518-y.CrossRefPubMed

31.

Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29(33):4452–61. doi:10.1200/JCO.2010.34.4879.CrossRefPubMedPubMedCentral

32.

De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005;11(13):4741–8. doi:10.1158/1078-0432.CCR-04-2569.CrossRefPubMed

33.

Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem. 2001;276(13):9817–24. doi:10.1074/jbc.M010840200M010840200.CrossRefPubMed

34.

Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, Holz MK. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem. 2009;284(10):6361–9. doi:10.1074/jbc.M807532200.CrossRefPubMed

35.

DeNardo DG, Cuba VL, Kim H, Wu K, Lee AV, Brown PH. Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth. Mol Cell Endocrinol. 2007;277(1–2):13–25. doi:10.1016/j.mce.2007.07.006.CrossRefPubMed

36.

Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 2011;13(2):R21. doi:10.1186/bcr2833.CrossRefPubMedPubMedCentral

37.

Voliva CF, Pecchi S, Burger M, Nagel T, Schnell C, Fritsch C et al. Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials. In: Proc AACR Annual Meeting, Washington, DC. Philadelphia (PA), EEUU, 2010.

38.

Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 2012;11(2):317–28. doi:10.1158/1535-7163.MCT-11-0474.CrossRefPubMed

39.

Schnell CR, Stauffer F, Allegrini PR, O’Reilly T, McSheehy PM, Dartois C, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res. 2008;68(16):6598–607. doi:10.1158/0008-5472.CAN-08-1044.CrossRefPubMed

40.

Graupera M, Guillermet-Guibert J, Foukas LC, Phng LK, Cain RJ, Salpekar A, et al. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature. 2008;453(7195):662–6. doi:10.1038/nature06892.CrossRefPubMed

41.

Yuan TL, Choi HS, Matsui A, Benes C, Lifshits E, Luo J, et al. Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci USA. 2008;105(28):9739–44. doi:10.1073/pnas.0804123105.CrossRefPubMedPubMedCentral

42.

Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legueux M, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther. 2012;11(8):1747–57. doi:10.1158/1535-7163.MCT-11-1021.CrossRefPubMed

43.

Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res. 2008;14(24):8010–8. doi:10.1158/1078-0432.CCR-08-1208.CrossRefPubMed

44.

Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2(11):1036–47. doi:10.1158/2159-8290.CD-11-0348.CrossRefPubMed

45.

Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012;2(11):1048–63. doi:10.1158/2159-8290.CD-11-0336.CrossRefPubMedPubMedCentral

46.

Rexer BN, Chanthaphaychith S, Dahlman KB, Arteaga CL. Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Res. 2014;16(1):R9. doi:10.1186/bcr3601.CrossRefPubMedPubMedCentral

47.

Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sanchez V, et al. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc Natl Acad Sci USA. 2013;110(35):14372–7. doi:10.1073/pnas.1303204110.CrossRefPubMedPubMedCentral

48.

Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282–90. doi:10.1200/JCO.2011.36.1360.CrossRefPubMed

49.

Baselga J, De Jonge MJ, Rodon J, Burris HA, Birle DC, De Buck SS et al. A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol. 2010;28:15s (suppl; abstr 3003).

50.

Grana B, Burris HA, Rodon Ahnert J, Abdul Razak AR, De Jonge MJ, Eskens F et al. Oral PI3Kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: an update on safety and efficacy. J Clin Oncol. 2011;29 (suppl; abstr 3043).

51.

Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, et al. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009;69(1):143–50. doi:10.1158/0008-5472.CAN-07-6656.CrossRefPubMedPubMedCentral

52.

Rodon J, Bendell JC, Abdul RAR, Homji N, Trandafir L, Quadt C et al. Safety profile and clinical activity of single-agent BKM120, a Pan-Class I PI3K inhibitor, for the treatment of patients with metastatic breast carcinoma. Cancer Res. 2011;71(suppl 24):Abstract P3-16-01. doi:10.1158/0008-5472.sabcs11-p3-16-01.

53.

Rodon J, Bendell J, Razak ARA, De Jonge M, Eskens F, Di Tomaso E et al. A phase I dose escalation and expansion trial of BKM120, an oral pan-PI3K inhibitor, in patients with advanced solid tumors: analysis of pharmacodynamic biomarker data. In: ESMO Meeting Abstracts, Vienna, Austria, 2012. vol 9. p. ix158 (Abstract 457P). doi:10.1093/annonc/mds395.

54.

Dirix L, Schuler M, Machiels J, Hess D, Awada A, Steeghs N et al. Phase IB dose-escalation study of BEZ235 or BKM120 in combination with paclitaxel (PTX) in patients with advanced solid tumors. In: ESMO Meeting Abstracts, Vienna, Austria, September 1 2012. vol 9. p. ix157 (Abstract 454P). doi:10.1093/annonc/mds395.

55.

Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, et al. Ph lb dose escalation study of oral pan-PI3K inhibitor buparlisib (BKM120) with oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with advanced solid tumours. Clin Cancer Res. 2014. doi:10.1158/1078-0432.ccr-14-1814.PubMed

56.

Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6(2):117–27. doi:10.1016/j.ccr.2004.06.022S1535610804002107.CrossRefPubMed

57.

Barbareschi M, Cuorvo LV, Girlando S, Bragantini E, Eccher C, Leonardi E, et al. PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Arch. 2012;461(2):129–39. doi:10.1007/s00428-012-1267-2.CrossRefPubMed

58.

Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, et al. Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clin Cancer Res. 2014;20(7):1935–45. doi:10.1158/1078-0432.CCR-13-1070.CrossRefPubMed

59.

Pistilli B, Urruticoechea A, Chan S, Han HS, Jerusalem G, Kong A et al. Ph Ib/II study of BKM120 plus trastuzumab in patients with trastuzumab-resistant HER2+ advanced breast cancer. In: ESMO Meeting Abstracts, Vienna, Austria, 2012. vol 9. p. ix116 (Abstract 3180).

60.

Mayer IA, Abramson VG, Balko JM, Isakoff SJ, Kuba MG, Sanders M et al. SU2C phase Ib study of pan-PI3K inhibitor BKM120 with letrozole in ER+/HER2− metastatic breast cancer (MBC). In: ASCO meeting abstracts, May 30 2012. vol suppl 15. p. Abstract 510.

61.

Estevez L, Suarez A, Calvo I, Fernandez-Abad M, Perea S, Hidalgo M. Abstract P4-15-09: an exploratory analysis of inactivation of PI3K/AKT/mTOR signaling pathway using neoadjuvant BKM120 in PI3KCA mutated early breast cancer. Cancer Res. 2013;73(24 Supplement):P4-15-09. doi:10.1158/0008-5472.sabcs13-p4-15-09.

Title: Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma
Authors: L. G. Estévez
E. García
M. Hidalgo
Publication date: 01-06-2016
Publisher: Springer Milan
Published in: Clinical and Translational Oncology / Issue 6/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-015-1410-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Visceral obesity stimulates anaphase bridge formation and spindle assembly checkpoint dysregulation in radioresistant oesophageal adenocarcinoma

Erratum to: Visceral obesity stimulates anaphase bridge formation and spindle assembly checkpoint dysregulation in radioresistant oesophageal adenocarcinoma

Molecular biology of testicular germ cell tumors

The position and current status of radiation therapy after primary systemic therapy in breast cancer: a national survey-based expert consensus statement

Concurrent chemo-radiotherapy in elderly patients: tolerance and compliance in a series of 137 patients

Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer